[go: up one dir, main page]

MA37850A1 - Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale - Google Patents

Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale

Info

Publication number
MA37850A1
MA37850A1 MA37850A MA37850A MA37850A1 MA 37850 A1 MA37850 A1 MA 37850A1 MA 37850 A MA37850 A MA 37850A MA 37850 A MA37850 A MA 37850A MA 37850 A1 MA37850 A1 MA 37850A1
Authority
MA
Morocco
Prior art keywords
atrial
nep
prodrug
treatment
pharmaceutically acceptable
Prior art date
Application number
MA37850A
Other languages
English (en)
Inventor
Christoph Schumacher
Thomas Holbro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49000959&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37850(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA37850A1 publication Critical patent/MA37850A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne le promédicament inhibiteur de nep ester éthylique de l'acide n-(3-carboxy-1-oxopropyl)-(4s)-p-phénylphénylméthyl)-4-amino-(2r)-méthylbutanoïque ou un sel pharmaceutiquement acceptable de celui-ci; ou l'inhibiteur de nep acide n-(3-carboxy-1-oxopropyl)-(4s)-p-phénylphénylmethyl)-4-amino-(2r)-méthylbutanoïque ou un sel pharmaceutiquement acceptable de celui-ci, un promédicament pour l'utilisation dans le traitement, la prévention ou le retard de la progression d'une maladie caractérisée par un agrandissement atrial et/ou une remodélisation atriale; une méthode de traitement, de prévention ou de retard de la progression d'une maladie caractérisée par un agrandissement atrial et/ou une remodélisation atriale, comprenant l'administration d'une quantité thérapeutiquement efficace ou d'une quantité prophylactiquement efficace de l'inhibiteur de nep ou du promédicament inhibiteur de nep, ou d'un promédicament sous forme de sel pharmaceutiquement acceptable de ceux-ci, à un sujet, par exemple un sujet humain, ayant besoin d'un tel traitement. La présente invention concerne en outre une composition pharmaceutique ou un conditionnement commercial comprenant l'inhibiteur de nep ou le promédicament inhibiteur de nep ou un sel pharmaceutiquement acceptable de ceux-ci, un promédicament pour l'utilisation dans le traitement, la prévention ou le retard de la progression d'une maladie caractérisée par un élargissement atrial et/ou une remodélisation atriale.
MA37850A 2012-08-24 2013-08-22 Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale MA37850A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261692911P 2012-08-24 2012-08-24
PCT/EP2013/067472 WO2014029848A1 (fr) 2012-08-24 2013-08-22 Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale

Publications (1)

Publication Number Publication Date
MA37850A1 true MA37850A1 (fr) 2018-07-31

Family

ID=49000959

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37850A MA37850A1 (fr) 2012-08-24 2013-08-22 Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale

Country Status (27)

Country Link
US (3) US9517226B2 (fr)
EP (2) EP2887961B1 (fr)
JP (4) JP6482462B2 (fr)
KR (2) KR102159601B1 (fr)
CN (2) CN108685889A (fr)
AU (1) AU2013304949C1 (fr)
BR (1) BR112015003067A2 (fr)
CA (1) CA2882771C (fr)
CL (1) CL2015000426A1 (fr)
DK (1) DK2887961T3 (fr)
ES (1) ES2879550T3 (fr)
HK (1) HK1205930A1 (fr)
HU (1) HUE054885T2 (fr)
IL (1) IL237114B (fr)
MA (1) MA37850A1 (fr)
MX (1) MX378867B (fr)
NZ (1) NZ704604A (fr)
PH (1) PH12015500375A1 (fr)
PL (1) PL2887961T3 (fr)
PT (1) PT2887961T (fr)
RU (1) RU2667643C2 (fr)
SG (1) SG11201500256UA (fr)
SI (1) SI2887961T1 (fr)
TN (1) TN2015000028A1 (fr)
TW (1) TWI634887B (fr)
WO (1) WO2014029848A1 (fr)
ZA (1) ZA201500262B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
BR112015003067A2 (pt) 2012-08-24 2017-07-04 Novartis Ag inibidores de nep para tratar doenças caracterizadas por alargamento ou remodelagem atrial
PT3626270T (pt) 2013-08-26 2024-01-11 Novartis Ag Tratamento de doenças cardiovasculares
WO2015128453A1 (fr) * 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Utilisation médicale d'un inhibiteur de dpp-4
CN106795099B (zh) * 2014-04-10 2019-11-26 南京奥昭生物科技有限公司 用于治疗高血压和心血管疾病的前药和组合物
HRP20230480T1 (hr) 2015-05-11 2023-07-21 Novartis Ag Režim doziranja sakubitrila i valsartana za liječenje zatajenja srca
WO2016193883A1 (fr) 2015-05-29 2016-12-08 Novartis Ag Sacubitril et valsartan pour le traitement d'une maladie métabolique
CN106309388A (zh) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 一种用于心衰治疗的药物组合物及其制备方法
WO2017006254A1 (fr) 2015-07-08 2017-01-12 Novartis Ag Combinaison de médicaments comprenant un antagoniste du récepteur de l'angiotensine ii, un inhibiteur d'endopeptidase neutre et un antagoniste du récepteur de minéralocorticoïdes
CN105997993B (zh) * 2015-07-11 2018-03-30 麦丽芳 一种用于心血管疾病治疗的固体口服型制剂及其制备方法
CN105997994A (zh) * 2015-07-11 2016-10-12 凌莉 一种固体口服型制剂及其制备方法
EP3355880A1 (fr) 2015-08-28 2018-08-08 Novartis AG Nouvelle utilisation
WO2017134597A1 (fr) 2016-02-03 2017-08-10 Novartis Ag Formes pharmaceutiques à base de composés organiques
US11382866B2 (en) 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
US20210177803A1 (en) 2018-08-23 2021-06-17 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (fr) 2018-08-24 2020-02-27 Novartis Ag Nouvelles combinaisons de médicaments
BR112021016198A2 (pt) 2019-03-08 2021-11-03 Boehringer Ingelheim Int Formulações de anticorpo anti-il-36r

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3004206A1 (de) 1980-02-06 1981-08-13 Hoechst Ag, 6000 Frankfurt Verfahren zur herstellung von 1-alkyl-1-phenylhydrazinen
DE3005674A1 (de) 1980-02-15 1981-08-20 Ruhr-Zink GmbH, 4354 Datteln Verwendung einer blei-legierung fuer anoden bei der elektrolytischen gewinnung von zink
DE3010374A1 (de) 1980-03-18 1981-10-08 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von copolymerisaten von styrol und/oder dessen derivaten
US4610816A (en) 1980-12-18 1986-09-09 Schering Corporation Substituted dipeptides as inhibitors of enkephalinases
US4383527A (en) 1981-02-20 1983-05-17 Howmedica, Inc. Device for guiding the insertion of surgical wires into bone tissue
DE3173350D1 (en) 1981-04-24 1986-02-13 Jean Martin Prefabricated unit for the realization of a construction frame
ZA84670B (en) 1983-01-31 1985-09-25 Merck & Co Inc Thiorphan analogs as enkephalinase and angiotensin converting enzyme inhibitors
US4722810A (en) 1984-08-16 1988-02-02 E. R. Squibb & Sons, Inc. Enkephalinase inhibitors
US4929641B1 (en) 1988-05-11 1994-08-30 Schering Corp Mercapto-acylamino acid antihypertensives
US4749688A (en) 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
US4740499A (en) 1986-07-28 1988-04-26 Monsanto Company Method of enhancing the bioactivity of atrial peptides
GB8811873D0 (en) 1988-05-19 1988-06-22 Pfizer Ltd Therapeutic agents
GB2218983A (en) 1988-05-27 1989-11-29 Pfizer Ltd Spiro-substituted glutaramides as diuretics
GB8812597D0 (en) 1988-05-27 1988-06-29 Pfizer Ltd Therapeutic agents
EP0361365A1 (fr) 1988-09-30 1990-04-04 E.R. SQUIBB & SONS, INC. Composés d'acides aminobenzoiques et aminocyclohexane carboxyliques, compositions, et méthode d'application
GB8903740D0 (en) 1989-02-18 1989-04-05 Pfizer Ltd Therapeutic agents
DE59107440D1 (de) 1990-02-19 1996-04-04 Ciba Geigy Ag Acylverbindungen
US5223516A (en) 1990-03-22 1993-06-29 E. R. Squibb & Sons, Inc. 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
US5294632A (en) 1991-05-01 1994-03-15 Ciba-Geigy Corporation Phosphono/biaryl substituted dipetide derivatives
US5250522A (en) 1992-10-09 1993-10-05 Ciba-Geigy Corporation Phosphono/biaryl substituted amino acid derivatives
US5273990A (en) 1992-09-03 1993-12-28 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives
GB9123353D0 (en) 1991-11-04 1991-12-18 Fujisawa Pharmaceutical Co New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
WO1993010773A1 (fr) 1991-12-06 1993-06-10 Schering-Plough S.P.A. Utilisation d'inhibiteurs d'endopeptidases neutres dans le traitement de l'hipertrophie ventriculaire gauche
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
DE4233296C1 (de) 1992-10-02 1994-03-31 Heitland Und Petre Int Gmbh Behälter für Kosmetikprodukte
WO1994015908A1 (fr) 1993-01-14 1994-07-21 Yoshitomi Pharmaceutical Industries, Ltd. Derive de propionamide et son utilisation medicinale
JPH06234754A (ja) 1993-02-10 1994-08-23 Dai Ichi Seiyaku Co Ltd 複素環式カルボン酸誘導体
IT1266571B1 (it) 1993-07-30 1997-01-09 Zambon Spa Derivati della beta-mercapto-propanammide utili nel trattamento delle malattie cardiovascolari
JP3576193B2 (ja) 1993-12-03 2004-10-13 第一製薬株式会社 ビフェニルメチル置換バレリルアミド誘導体
US6201002B1 (en) 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
EP1467728B1 (fr) * 2002-01-17 2007-08-22 Novartis AG Compositions pharmaceutiques a base de valsartan et d'inhibiteurs nep
RU2245162C2 (ru) * 2003-01-04 2005-01-27 Козлов Владимир Александрович Способ терапии инфаркта миокарда
JP4783733B2 (ja) 2003-05-16 2011-09-28 ノバルティス アーゲー バルサルタンを含む医薬組成物
MY146830A (en) 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP4186491A1 (fr) 2007-11-06 2023-05-31 Novartis AG Compositions pharmaceutiques
ES2702529T3 (es) * 2010-08-24 2019-03-01 Novartis Ag Una composición farmacéutica para uso en la prevención o tratamiento de la insuficiencia cardíaca en un mamífero que recibe terapia anticoagulante
BR112015003067A2 (pt) 2012-08-24 2017-07-04 Novartis Ag inibidores de nep para tratar doenças caracterizadas por alargamento ou remodelagem atrial

Also Published As

Publication number Publication date
DK2887961T3 (da) 2021-07-19
AU2013304949C1 (en) 2020-12-24
RU2018126749A3 (fr) 2021-12-28
KR20150046039A (ko) 2015-04-29
CA2882771A1 (fr) 2014-02-27
PH12015500375A1 (en) 2015-04-20
JP7407508B2 (ja) 2024-01-04
ES2879550T3 (es) 2021-11-22
BR112015003067A2 (pt) 2017-07-04
JP2015526458A (ja) 2015-09-10
NZ704604A (en) 2018-06-29
MX2015002432A (es) 2015-06-22
SG11201500256UA (en) 2015-04-29
JP2023159114A (ja) 2023-10-31
TW201414471A (zh) 2014-04-16
AU2013304949B2 (en) 2016-08-11
JP2019069954A (ja) 2019-05-09
HK1205930A1 (en) 2015-12-31
IL237114A0 (en) 2015-03-31
US20150190376A1 (en) 2015-07-09
TN2015000028A1 (en) 2016-06-29
US11135192B2 (en) 2021-10-05
US20170049738A1 (en) 2017-02-23
EP3943084A1 (fr) 2022-01-26
JP6482462B2 (ja) 2019-03-13
CL2015000426A1 (es) 2015-10-02
KR102159601B1 (ko) 2020-09-28
TWI634887B (zh) 2018-09-11
EP2887961A1 (fr) 2015-07-01
EP2887961B1 (fr) 2021-04-28
PL2887961T3 (pl) 2021-11-08
MX378867B (es) 2025-03-11
RU2015110240A (ru) 2016-10-20
WO2014029848A1 (fr) 2014-02-27
US20180200218A1 (en) 2018-07-19
ZA201500262B (en) 2016-09-28
RU2018126749A (ru) 2019-03-12
JP2022020624A (ja) 2022-02-01
RU2667643C2 (ru) 2018-09-21
CN108685889A (zh) 2018-10-23
US9517226B2 (en) 2016-12-13
CN104602711A (zh) 2015-05-06
CA2882771C (fr) 2021-02-23
IL237114B (en) 2020-10-29
AU2013304949A1 (en) 2015-02-05
HUE054885T2 (hu) 2021-10-28
US9937143B2 (en) 2018-04-10
PT2887961T (pt) 2021-07-28
KR20200111822A (ko) 2020-09-29
SI2887961T1 (sl) 2021-08-31

Similar Documents

Publication Publication Date Title
MA37850A1 (fr) Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale
MA48051B1 (fr) Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide
MA41496B1 (fr) Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
MA35513B1 (fr) Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA37763B1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1
MA55199B1 (fr) (n-)acétyl-l-leucine pour le traitement des lésions cérébrales traumatiques
MA39186A1 (fr) Dérivés de [1,2,4]triazolo[1,5-a]pyrimidine utilisés comme inhibiteurs du protéasome des protozoaires pour le traitement de maladies parasitaires comme la leishmaniose
MA38694B1 (fr) Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase
WO2019032528A8 (fr) Inhibiteurs bicycliques d'histone désacétylase
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EA202191150A1 (ru) Ингибиторы аминопептидазы а и содержащие их фармацевтические композиции
MA41985B1 (fr) Composition pour le nettoyage du côlon et le traitement de troubles gastro-intestinaux
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine
MA33455B1 (fr) Otamixaban pour le traitement de patients atteints d'infarctus du myocarde sans élévation du st ages et insuffisants renaux
MX2021006210A (es) Metodos para diagnosticar y/o tratar una hepatopatia, nefropatia o neumopatia aguda o cronica.
FR3050112B1 (fr) Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques